Spyre Therapeutics (SYRE) Cash & Equivalents (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Cash & Equivalents data on file, last reported at $95.4 million in Q1 2026.

• Quarterly Cash & Equivalents rose 96.83% year-over-year to $95.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.4 million (up 96.83% YoY) and the FY2025 annual result came in at $85.7 million, down 2.29% from the prior year.
• Cash & Equivalents rose to $95.4 million in Q1 2026, from $85.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $235.4 million in Q2 2023 to a low of $14.6 million in Q1 2022.
• A 5-year average of $87.2 million and a median of $71.6 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 81.76% — and 2024, when it surged 545.67%.
• Tracing SYRE's Cash & Equivalents over 5 years: stood at $34.9 million in 2022, then surged by 441.82% to $188.9 million in 2023, then plunged by 53.55% to $87.7 million in 2024, then fell by 2.29% to $85.7 million in 2025, then rose by 11.35% to $95.4 million in 2026.
• The last three Cash & Equivalents figures came in at $95.4 million (Q1 2026), $85.7 million (Q4 2025), and $64.9 million (Q3 2025), per Business Quant data.